Jennewein Biotechnologie

Management

Jennewein Biotechnologie – an industrial biotechnology company

The Jennewein Biotechnologie is an industrial biotechnology company, which manufactures mono- and oligosaccharides. Of particular interest is here the production of high quality oligosaccharides with his application in the food and pharmaceutical sector.

 

Stefan Jennewein

Dr. Stefan Jennewein studied Biochemistry, Pharmacology and Organic Chemistry at the Universities of Sussex (Brighton, UK), Zurich (CH), Tübingen (D) and Cambridge (UK), and at the Ludwig-Maximilians-Universität (Munich, D). Dr. Stefan Jennewein also gained practical experience through his work at Washington State University (Pullman, USA), the company DSM N.V. (Delft, NL), the Technical University of Darmstadt (D), and the Fraunhofer Institute for Molecular Biology and Applied Ecology (Aachen, D). Dr. Stefan Jennewein in his position as CEO is responsible for research and development, regulatory issues, and sales at Jennewein Biotechnologie.

 

Klaus Jennewein

Dr. Klaus Jennewein studied economics and business studies at the universities of Sussex at Brighton (UK) and Pierre Mendès France at Grenoble (F). Klaus Jennewein holds a PhD in innovation management and intellectual property management of the University of Hohenheim at Stuttgart (D) and École Central Paris (F). Dr. Jennewein held various senior management positions in particular with responsibilities for strategy, marketing and sales. In 2005 Dr. Klaus Jennewein founded Jennewein Biotechnologie together with his brother Dr. Stefan Jennewein. In his current position as CEO Dr. Klaus Jennewein is responsible for strategy and partner management.

 

Stephan Michel

Stephan Michel studied Business Administration in Bielefeld and Düsseldorf. He gained practical experience through his work as an audit manager at KPMG before, at the beginning of 2002, he moved to the Holding of the Karstadt-Quelle enterprise in Essen. There he established and developed the Services Subgroup and directed the bookkeeping of the Holding company, who had more than 5000 employees and total assets of 1,3 billion. Subsequently he worked as CFO at the medium-sized IT service company EDS ITelium GmbH and later as CFO Europe at the Reutax group in Heidelberg. From 2013 until summer 2016 he worked as Managing Director for the Pawlowsky Consultancy GmbH. Since the beginning of 2016 he was first responsible at Jennewein Biotechnologie GmbH on an interim basis for the human resources and finance division, before he has assumed in August 2016 the position as CFO.

 

Glyn Brookman

Glyn Brookman started his business life at the NatWest Bank International training Center in Kings Cross, London UK, as an office Junior. From there he moved to a higher position within the bank as an accounting support clerk, and then on to the stock broking arm of County NatWest Stockbrokers as a member of the support staff to the Broker floor, where he gained valuable experience in the London financial markets. He then moved into the world of money Broking where he worked as a Sterling Money Broker, at Butler Harlow Ueda Ltd. next to London Bridge. He moved to Germany in February of 1995 and took up the roll of Key Account Manager and then Group leader of the Automotive arm of Maxim Integrated Products. Since spring 2016 he is Director Sales and Authorized Officer at the Jennewein Biotechnologie GmbH.

 

Benedikt Engels

Dr. Benedikt Engels studied Bioengineering at the University of Applied Science, Division Jülich. Subsequently he worked as a scientific employee at the Department of Industrial Biotechnology at the Fraunhofer Institute for Molecular Biology and Applied Ecology in Aachen, where he received his PhD from RWTA Aachen University. After a period as Postdoc at the Fraunhofer Institute he joined Jennewein Biotechnologie GmbH in July 2014 as Head of Analytics in the R&D Department. Since spring 2016 he has assumed the position of Head of Production and Authorized Officer at the Jennewein Biotechnologie GmbH.

 

Andreas Hübel

Dr. Andreas Hübel studied Biology at the University of Hamburg and received his PhD for his scientific research in the field of Molecular Parasitology at the Bernhard-Nocht-Institute of Tropical Medicine. Thereafter he conducted research as postdoctoral fellow and scientific employee at Harvard Medical School, Washington University School of Medicine, and Philipps University Marburg, before he qualified as German and European Patent Attorney. He worked as freelance patent attorney for a few patent law firms, the last four years before joining Jennewein Biotechnologie GmbH as partner of the patent law firm Michalski Hüttermann & Partner in Düsseldorf. Since fall 2016 he is Head of Intellectual property at Jennewein Biotechnologie GmbH.

 

Katja Parschat

Dr. Katja Parschat received a diploma in biology from the Carl von Ossietzky University in Oldenburg and her PhD from the department of Microbiology at the same University. In 2003 she started as post-doc at the department of Molecular Microbiology and Biotechnology at the Westfälische Wilhelms University in Münster. In 2010 she started at Jennewein Biotechnologie as senior scientist with responsibility for strain development for the production of HMOs and rare monosaccharides. After leading different teams within the R&D department she was assigned Deputy head of R&D in 2017. At the same time she got responsible for conducting the first clinical trial at the company.

 

Julia Parkot

Dr. Julia Parkot received her diploma degree from RWTH Aachen University and a Ph.D. from Heinrich-Heine-University Düsseldorf. After postdoctoral research at the Fraunhofer Institute of Molecular Biology and Applied Ecology in Aachen, Dr. Parkot joined Jennewein Biotechnologie in January 2008. Initially Dr. Parkot worked as senior scientist and lab head in strain and process development. In 2013, she took on the role as Head of Quality Control and Quality Management and was responsible for the development of quality control methods and building the quality management system of Jennewein Biotechnologie GmbH. Since April 2019, she is as Head of Quality and Regulatory Affairs also responsible for the international product approval.